| 主权项 |
1. A method comprising the following steps:
(a) administering to a subject of a mood disorder characterised by abnormal expression of peripheral benzodiazepine receptors (PBR) an in vivo imaging agent of Formula I:wherein:
R1 is C1-3 alkyl or C1-3 fluoroalkyl; R2 is hydrogen, hydroxyl, halo, cyano, C1-3 alkyl, C1-3 alkoxy, C1-3 fluoroalkyl, or C1-3 fluoroalkoxy; R3 and R4 are independently C1-3 alkyl, C7-10 aralkyl, or R3 and R4, together with the nitrogen to which they are attached, form a nitrogen-containing C4-6 aliphatic ring optionally comprising 1 further heteroatom selected from nitrogen, oxygen and sulfur; Y1 is O, S, SO, SO2 or CH2; and, Y2 is CH2, CH2—CH2, CH(CH3)—CH2 or CH2—CH2—CH2; and wherein Formula I as defined comprises an atom which is a radioisotope suitable for in vivo imaging; (b) allowing said administered in vivo imaging agent of step (a) to bind to peripheral benzodiazepine receptors (PBR) expressed in said subject; (c) detecting signals emitted by the radioisotope of said bound in vivo imaging agent of step (b) using a suitable in vivo imaging procedure; (d) generating an image representative of the distribution and/or extent of said signals detected in step (c); (e) determining the distribution and/or extent of PBR expression in said subject wherein said expression is directly correlated with the distribution and/or extent of said signals as represented in said image generated in step (d); and, (f) using the distribution and extent of PBR expression as determined in step (e) in the diagnosis and/or monitoring of said mood disorder. |
